Buy Fortis Healthcare Ltd for the Target Rs.1,100 by Motilal Oswal Financial Services Ltd
* After the change in promoter ownership to IHH Healthcare in FY19, Fortis Healthcare (FORH) has undergone a structural transformation, from a stressed, governance-challenged asset to a professionally managed, execution-led hospital platform. The transition was marked by balance sheet clean-up, exit of non-core assets, and strengthening of governance practices
* Since then, FORH has delivered a steady improvement in operating performance, from sales/EBITDA of INR45b/INR2b and a loss of INR1.5b in FY18 to sales/EBITDA/ PAT of INR90b/INR20.5b/INR10.8b over FY26E.
* During FY18-FY26, FORH has significantly increased its bed capacity and improved its operational efficiency, driving a 33% CAGR in EBITDA.
* Interestingly, FORH is now in a comfortable position to fund brownfield bed additions of 400-500 annually over the next five years through internal accruals and explore any inorganic opportunities.
* Agilus Diagnostics, its diagnostics division, is emerging from a transition-heavy phase (brand migration, litigation and portfolio rationalization), with early recovery visible in volumes and realization (~8% YoY sales growth for 9MFY26 vs. 4% in FY25). Utilization-led growth, an improving test mix and hospital integration are expected to drive steady revenue growth and gradual margin expansion ahead.
* Overall, we estimate FORH to deliver a CAGR of 17%/22% in EBITDA/PAT over FY26-28, driven by a) healthy patient volume growth, b) bed additions to support a higher number of patient treatments, c) price hikes and optimization of case mix and payor mix, and d) steady growth in test volume in diagnostics business.
* We value FORH on the SoTP basis, valuing the hospital business at 30x 12M fwd EV/EBITDA and the diagnostics business at 23x 12M fwd EV/EBITDA, to arrive at a TP of INR1,100. We have assigned EV/EBITDA multiple in line with peers (MAXH/APHS) to factor in a) the robust transformation in the existing business, b) a brownfield strategy of bed additions driving faster EBITDA break-even, and c) subsequently driving better return ratios. We initiate coverage on FORH with a BUY rating.
Hospitals: Core growth engine with improving mix and scalable expansion
* FORH operates a diversified pan-India hospital network (36 facilities, 6,000+ beds), with strong regional presence (North: 3,443 beds; South: 1,400 beds), providing a resilient and scalable growth base.
* The portfolio is increasingly tilted toward higher-acuity specialties, with CONGO mix at ~55% (+650bp vs. FY22), supporting ARPOB growth (~INR24-26m; ~10% CAGR) and improved revenue quality. CONGO represents a specialty mix of Cardiac, Onco, Neuro, Gastro, and Orthopedic services.
* Occupancy is stable at ~65-70%, indicating strong demand absorption and utilization.
* Expansion is driven by a cluster-led brownfield strategy and operations & management (O&M) partnerships, with 3,200+ bed additions planned by FY30, enabling a capital-efficient scale-up.
* Profitability is improving, with ~64% of beds operating at >20% EBITDA margins (vs. ~57% bed in FY22) and a sharp reduction in low-margin beds, while new facilities (Manesar, Jaipur) provide further upside through ramp-up.
* Over FY26-FY28E, we expect growth to be led by capacity expansion, with operating bed capacity estimated to expand at ~13% CAGR and ARPOB expected to clock ~2% CAGR, together driving revenue/EBITDA CAGRs of ~16%/19%, with margins trending toward ~23%.
* Diagnostics: Transition behind, recovery underway with utilization-led upside
* Agilus operates a large diagnostics network (400+ labs across ~500+ districts), conducting ~39m tests for ~16m patients (FY25), indicating relatively low throughput per lab and underutilized infrastructure.
* The FY23-25 period represented a transition phase, impacted by brand-related disruptions. The company incurred annual costs of ~INR500-600m related to brand transition (Agilus brand creation), alongside legal overhangs of the SRL brand, which delayed execution and impacted growth and profitability, particularly in the B2C segment and clinician adoption.
* Execution challenges during this phase, including litigation-led pauses in brand migration, led to slower volume growth (patients ~16-16.5m) and subdued profitability, despite the underlying scale of the network.
* Additionally, the business exited low-ticket government contracts such as Mohalla Clinic partnerships, which impacted volumes in the near term but helped improve overall revenue quality and realizations.
* With these issues largely resolved, including the re-acquisition of the SRL brand, the business has started to show early signs of recovery in FY26, supported by stabilizing volumes and improving realizations (ARPP/ARPT of INR894/INR369 in 9MFY26 vs. INR808/INR344 in FY23).
* Mix is gradually improving, with specialized tests at ~34% and wellness tests at ~12-13%, supporting realization-led growth. Integration with hospitals provides a captive referral funnel to drive utilization.
* Over FY26-FY28E, diagnostics revenue/EBITDA are expected to clock a CAGR of ~9%/11%, with margins gradually improving toward ~24%, driven by post-transition normalization, utilization ramp-up and hospital integration.
IHH as parent: Strategic sponsor enabling integration, scale and execution
* FORH is backed by IHH Healthcare, which operates 80+ hospitals across 10+ countries, providing global clinical expertise and operating frameworks.
* IHH has delivered ~10.7% revenue CAGR over FY21-25, with stable EBITDA margins (22-25%) and moderate leverage (Net Debt/EBITDA ~2.4x), supporting capital deployment.
* India is a core strategic market, with Fortis positioned as the primary platform for expansion under IHH’s 2030 strategy.
* The Fortis-Gleneagles O&M integration (900+ beds under Gleneagles India) positions Fortis as the operational hub, enabling asset-light expansion and clinical synergies.
* Gleneagles’ transplant expertise and global brand presence (Singapore, Malaysia, Brunei, Hong Kong, India) enhance Fortis’ clinical positioning and international patient flows.
Financials: Improving trajectory with near-term investment phase
* Revenue and EBITDA are expected to clock ~15% and ~17% CAGR, respectively, over FY26-FY28E, driven primarily by hospital expansion and ARPOB growth.
* EBITDA margins are projected to expand to ~23-24%, supported by case mix improvement and operating leverage. Effectively, Adj. PAT is expected to clock 21.5% CAGR over FY26-28 to INR16b.
* FORH is expected to generate strong operating cash flows (~INR15-20b annually), supporting 750-1,000 beds/year expansion with controlled leverage.
* The company is entering a higher capex phase (INR12-13b annually), which may moderate FCF in the near term (e.g., ~INR3.6b in FY26E) before recovering to ~INR8-9b by FY28E.
* Return ratios are improving, with ROE expected to increase from ~10% (FY25) to ~13% (FY28E) and ROCE to ~12-13%, driven by better utilization, margins and asset turns.
Valuation and view: Initiate coverage with BUY rating
* We model EBITDA CAGR of 19%/11% for Hospitals/Diagnostics over FY26-28E under our base case scenario. We also assign a 24-month forward EV/EBITDA multiple of 30x/23x for Hospitals/Diagnostics to arrive at our TP of INR1,100, implying a potential upside of 19%.
* The bull case scenario estimates EBITDA CAGR of 22%/14% for Hospitals/Diagnostics over FY26-28, driven by an improving hospital case mix, timely ramp-up of new facilities, and a favorable diagnostics product mix, supported by stronger operational efficiencies. Applying a 24-month forward EV/EBITDA multiple of 33x/25x for Hospitals/Diagnostics, we derive a TP of INR1,260, implying a 36% upside from the current levels.
* The bear case scenario builds in EBITDA CAGR of 16%/8% for Hospitals/Diagnostics over FY26-28, reflecting higher competitive intensity, an unfavorable hospital case mix, weaker diagnostics product mix, slower-than-expected ramp-up of facilities, and higher operational inefficiencies. Applying a 24-month forward EV/EBITDA multiple of 24x/19x for Hospitals/Diagnostics, we derive a TP of INR790, implying a 15% downside from the current levels.
* We initiate coverage on FORH with a BUY rating.
Key risks
* Changes in healthcare regulations, pricing controls, or compliance requirements that could affect operations and profitability.
* Shortages of skilled doctors, nurses, and specialists, along with increasing compensation costs.
* Delays, cost overruns, or underperformance in hospital expansions, acquisitions, or restructuring initiatives.
* Rising costs of medical consumables, equipment, energy, and technology that may pressure margins.
* Fluctuations in patient volumes, especially for elective procedures, due to economic or public health factors.
* Disputes, unfavorable terms, or delayed payments from insurance partners affecting cash flows and patient access.
* Regional geopolitical tensions or cross-border disruptions impacting demand and operations.
For More Motilal Oswal Securities Ltd Disclaimer
http://www.motilaloswal.com/MOSLdisclaimer/disclaimer.html
SEBI Registration number is INH00000041
